HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin (Chemical-based HPAPIs and Biologic-based HPAPIs), by Manufacturing Location (In-house Manufacturing and Outsourcing), by Drug Type (Novel HPAPIs and Generic HPAPIs), by Type of Pharmacologic

HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin (Chemical-based HPAPIs and Biologic-based HPAPIs), by Manufacturing Location (In-house Manufacturing and Outsourcing), by Drug Type (Novel HPAPIs and Generic HPAPIs), by Type of Pharmacological Molecule (Small Molecules and Biologics), by Application (Oncology, Respiratory, Ophthalmic Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Highly potent active pharmaceutical ingredients (HPAPI) has an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments. Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.
Cytotoxic drugs are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms.
Market Dynamics
Market players are engaged in inorganic activities, such as acquisitions, in order to expand its product portfolio, this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in January 2019, Flamma Group, a life science company, acquired Teva’s Chemical Synthesis Center, the 40,000 sq. ft. cGMP facility in Malvern (U.S.). This laboratory and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, and 1 cGMP HPAPI kilo lab suite.
Key players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in December 2019, Cerbios-Pharma SA announced the authorization by Swissmedic of its cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).
Moreover, in December 2019, Piramal Pharma Solutions, a division of Piramal Enterprises ltd., expanded its manufacturing facility in Riverview, Michigan, with an investment of approximately US$ 32 million to develop and manufacture potent and non-potent active pharmaceutical ingredients (API).
Key features of the study:
This report provides an in-depth analysis of the global HPAPIs and cytotoxic drugs manufacturing market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global HPAPIs and cytotoxic drugs manufacturing market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global HPAPIs and cytotoxic drugs manufacturing market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HPAPIs and cytotoxic drugs manufacturing market
Detailed Segmentation:
Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin:
Chemical-based HPAPIs
Biologic-based HPAPIs
Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location:
In-house Manufacturing
Outsourcing
Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type:
Novel HPAPIs
Generic HPAPIs
Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule:
Small Molecules
Biologics
Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application:
Oncology
Respiratory
Ophthalmic Disorders
Others
Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region:
North America
By Country:
U.S.
Canada
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Country:
GCC
Israel
Rest of Middle East
Africa
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Pfizer, Inc.
Lonza Group
CordenPharma International
Evonik Industries AG
Flamma Group
Merck KGaA
CARBOGEN AMCIS
Catalent, Inc.
Piramal Enterprises Ltd.
AbbVie Inc.
Fareva Group
Cerbios-Pharma SA
Novasep
Ajinomoto Bio-Pharma
PCI Pharma Services
Sterling Pharma Solutions
Heraeus Holding
Polpharma Biologics
Helsinn Healthcare SA
Seqens
Cambrex Corporation
“*” marked represents similar segmentation in other categories in the respective section.